Novo Nordisk
Novo Nordisk markets GLP-1 medicines for other indications and is testing semaglutide in Alzheimer’s EVOKE trials.
Overview
Diabetes/obesity labels do not equal a dementia indication. EVOKE is investigational. Not investment advice.
Scorecard
All companies- phase 3 +3
- modalities +2
Semaglutide is FDA-approved for other indications. Alzheimer’s disease use remains investigational in Phase 3 EVOKE studies — not a dementia label.
Similar pages
not linked directly; found by shared links- PersonAlois Alzheimer
Shares Alzheimer’s disease and the tag dementia-atlas.
- TreatmentBrexpiprazole
Shares Alzheimer’s disease and the tag dementia-atlas.
- CollectionClinicalTrials.gov
Shares Alzheimer’s disease and the tag dementia-atlas.
- TreatmentMemantine
Shares Alzheimer’s disease and the tag dementia-atlas.
- InstitutionNational Institute on Aging
Shares Alzheimer’s disease and the tag dementia-atlas.
- TechnologyCSF amyloid and tau
Shares Alzheimer’s disease and the tag dementia-atlas.
- InstitutionUCL
Shares Alzheimer’s disease and the tag dementia-atlas.
- DiagnosisMild cognitive impairment
Shares Semaglutide (EVOKE programme), Alzheimer’s disease and the tag dementia-atlas.